TESARX / ABOUT
About Tesarx
A plainly filed data sheet on the peer-reviewed tesamorelin literature — what it is, what it is not, and the exact scope of what the record supports.
What Tesarx is
Tesarx files the peer-reviewed research literature on tesamorelin as a flat, hard-bordered data sheet — every figure logged straight to its study. No clinic or pharmacy stands behind it; no one here sees patients, writes prescriptions, or fills them, and there is nothing to purchase. The pages log what the published science reports and cite each figure to source — they do not diagnose, treat, or counsel.
The "rx" in the name is editorial framing — a position this publisher occupies relative to the literature, signaling that the focus is the prescription-drug record and its boundaries. It is not a claim that this site prescribes, dispenses, or fills anything. There is no pharmacy, no consultation, and no treatment offered here.
FDA-approval scope
We treat scope as the first fact, not a footnote. Tesamorelin is FDA-approved (NDA 022505, 2010) only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy [5]. That single indication is the approved use. General or cosmetic weight loss, anti-aging, performance enhancement, non-HIV fatty-liver treatment, and growth-hormone optimization are all off-label and not FDA-approved.
Wherever this site discusses a use outside the approved indication, that boundary is marked. The pivotal efficacy was demonstrated in HIV-positive adults on antiretroviral therapy [1]; generalization beyond that population is mechanistically plausible but not established by large RCTs [12]. Tesamorelin is also prohibited in sport under the WADA Prohibited List (category S2).
Why tesamorelin is costly
Two practical realities shape access to the approved product: high pharmaceutical cost and injection-only administration. The approved drug is a once-daily subcutaneous injection requiring reconstitution and refrigerated storage [13], and its price has been a recurring point in the access conversation around the compound.
Research-grade material sold for laboratory use is a separate category from the approved finished drug; it lacks the purity and potency oversight of the approved product. This site reports the literature and the record; it does not list, price, or sell anything, and it carries no vendor or purchase information.
How we handle the evidence
Every quantitative claim on this site maps to a numbered citation in the reference list — a peer-reviewed study, the FDA-approved labeling, or the NIH LiverTox monograph. We lead with what was measured and attribute it to its source. Where the data is precise, we state it precisely; where a question is unsettled, we say so. We do not extrapolate beyond what the studies report, and we do not present research-grade tesamorelin as a medicine to self-administer.